Response to the letter of Peng Bai and Jun Zhang on Cost-effectiveness of Adjuvant Alectinib in ALK-positive NSCLC-Considerations for Broader Applicability. - Supiot R; du Manoir de Juaye L; Chouaid C (Lung cancer (Amsterdam, Netherlands), 2026)